Research programme: RNA cell therapeutics - Cartesian Therapeutics
Alternative Names: In vivo LN transfection - Cartesian Therapeutics; rLN transfection - Cartesian TherapeuticsLatest Information Update: 08 Dec 2023
At a glance
- Originator Cartesian Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 01 Dec 2023 Research programme: RNA cell therapeutics - Cartesian Therapeutics is available for licensing as of 01 Dec 2023. https://www.cartesiantherapeutics.com/investors/
- 30 Nov 2023 Preclinical trials in Autoimmune disorders in USA (unspecified route) prior to November 2023 (Cartesian Therapeutics pipeline, November 2023)
- 08 Sep 2023 Cartesian Therapeutics and Biogen enters into a patent license agreement for T-cell modified with an mRNA